Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

W. Taylor Kimberly; John F. O’Sullivan; Anjali K. Nath; Michelle Keyes; Xu Shi; Martin G. Larson; Qiong Yang; Michelle T. Long; Ramachandran Vasan; Randall T. Peterson; Thomas J. Wang; Kathleen E. Corey; Robert E. Gerszten

doi:10.1172/jci.insight.92989

Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

W. Taylor Kimberly, John F. O’Sullivan, Anjali K. Nath, Michelle Keyes, Xu Shi, Martin G. Larson, Qiong Yang, Michelle T. Long, Ramachandran Vasan, Randall T. Peterson, Thomas J. Wang, Kathleen E. Corey, Robert E. Gerszten

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

Original language	English (US)
Article number	e92989
Journal	JCI Insight
Volume	2
Issue number	9
DOIs	https://doi.org/10.1172/jci.insight.92989
State	Published - May 4 2017
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1172/jci.insight.92989

Cite this

@article{6a092afd7c46476183958536bd7e757c,

title = "Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis",

abstract = "The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.",

author = "Kimberly, {W. Taylor} and O{\textquoteright}Sullivan, {John F.} and Nath, {Anjali K.} and Michelle Keyes and Xu Shi and Larson, {Martin G.} and Qiong Yang and Long, {Michelle T.} and Ramachandran Vasan and Peterson, {Randall T.} and Wang, {Thomas J.} and Corey, {Kathleen E.} and Gerszten, {Robert E.}",

note = "Funding Information: This study was supported by NIH grant K23NS076597 and R01NS099209 (to WTK), American Heart Association grant 14GRNT19060044 (to WTK), NIH grant K23DK99422 (to KEC), and NIH grants R01HL098280, U01DK048489, and R01DK081572 (to REG). Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Investigation. All rights reserved.",

year = "2017",

month = may,

day = "4",

doi = "10.1172/jci.insight.92989",

language = "English (US)",

volume = "2",

journal = "JCI Insight",

issn = "2379-3708",

publisher = "The American Society for Clinical Investigation",

number = "9",

}

TY - JOUR

T1 - Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

AU - Kimberly, W. Taylor

AU - O’Sullivan, John F.

AU - Nath, Anjali K.

AU - Keyes, Michelle

AU - Shi, Xu

AU - Larson, Martin G.

AU - Yang, Qiong

AU - Long, Michelle T.

AU - Vasan, Ramachandran

AU - Peterson, Randall T.

AU - Wang, Thomas J.

AU - Corey, Kathleen E.

AU - Gerszten, Robert E.

N1 - Funding Information: This study was supported by NIH grant K23NS076597 and R01NS099209 (to WTK), American Heart Association grant 14GRNT19060044 (to WTK), NIH grant K23DK99422 (to KEC), and NIH grants R01HL098280, U01DK048489, and R01DK081572 (to REG). Publisher Copyright: © 2017 American Society for Clinical Investigation. All rights reserved.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

AB - The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

UR - http://www.scopus.com/inward/record.url?scp=85048177065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048177065&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.92989

DO - 10.1172/jci.insight.92989

M3 - Article

C2 - 28469090

AN - SCOPUS:85048177065

SN - 2379-3708

VL - 2

JO - JCI Insight

JF - JCI Insight

IS - 9

M1 - e92989

ER -

Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this